AWM
DNA icon

Axxcess Wealth Management’s Ginkgo Bioworks DNA Stock Holding History

Axxcess Wealth Management’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,316
Closed -$17.6K – 902
2024
Q2 		$17.6K Sell
1,316
-3,649
-73% -$109K ﹤0.01% 839
2024
Q1 		$230K Buy
4,965
+1,295
+35% +$67K 0.01% 760
2023
Q4 		$248K Sell
3,670
-350
-9% -$21.4K 0.01% 713
2023
Q3 		$291K Buy
4,020
+1,572
+64% +$126K 0.01% 605
2023
Q2 		$182K Buy
2,448
+505
+26% +$29.9K 0.01% 559
2023
Q1 		$103K Buy
1,943
+632
+48% +$40K 0.01% 616
2022
Q4 		$88.6K Sell
1,311
-336
-20% -$30.9K 0.01% 596
2022
Q3 		$206K Sell
1,647
-113
-6% -$13.5K 0.02% 495
2022
Q2 		$168K Buy
1,760
+671
+62% +$81.8K 0.02% 503
2022
Q1 		$176K Buy
+1,089
New +$212K 0.01% 597

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Axxcess Wealth Management's DNA Position: Q3 2024 in Review

Axxcess Wealth Management sold out of Ginkgo Bioworks (DNA) in Q3 2024, closing a stake of 1,316 shares — an estimated $17.6K sold.

Axxcess Wealth Management first reported a position in DNA in Q1 2022 and held it in 10 quarters. The position peaked at $291K in Q3 2023. 159 funds tracked by Wall St. Rank hold DNA as of Q3 2024.

  • Axxcess Wealth Management reported no remaining Ginkgo Bioworks position as of Q3 2024 after selling out during the quarter.
  • Axxcess Wealth Management sold 1,316 Ginkgo Bioworks shares in Q3 2024, an estimated $17.6K.
  • Axxcess Wealth Management first reported a position in Ginkgo Bioworks in Q1 2022 and held it in 10 quarters.
  • Axxcess Wealth Management's Ginkgo Bioworks position peaked at $291K in Q3 2023.
  • 159 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2024.

Based on Axxcess Wealth Management's 13F filing for Q3 2024, filed 4 Nov 2024.